RT Journal Article
SR Electronic
A1 Helwick, Caroline
T1 Trial Results Establish Clinical Benefit of RAD001 in Advanced Renal Cell Carcinoma
JF MD Conference Express
YR 2008
FD SAGE Publications
VO 8
IS 4
SP 11
OP 11
DO 10.1177/155989770800800406
UL http://mdc.sagepub.com/content/8/4/11.abstract
AB Late-breaking results from a phase 3, randomized, double-blind, multicenter study provide convincing evidence that RAD001 is a safe and effective treatment for patients with metastatic renal cell carcinoma and validate mTOR inhibition as a cancer treatment.